伏立康唑
医学
耐火材料(行星科学)
外科
曲菌病
不利影响
土曲霉
麻醉
皮肤病科
内科学
抗真菌
微生物学
生物
天体生物学
物理
免疫学
作者
Shoude Zhang,Maojun Jin,Sideng Hu,Yuejiao Zhang,Guojin Zhou
标识
DOI:10.1177/0003489420946783
摘要
Refractory otomycosis is a common condition that is difficult to treat.This study aimed to evaluate the effectiveness of 1% topical voriconazole drops in the treatment of otomycosis.This retrospective analysis was conducted from November 2017 to November 2019. Patients who had refractory otomycosis without tympanic membrane perforation confirmed by microbial culture and fluorescent staining were included in the study. All patients were treated with 1% topical voriconazole drops hourly at daytime for 2 weeks. Evaluation of effectiveness was conducted 1 month after the completion of topical voriconazole treatment. Before and after topical voriconazole treatment, hearing tests were performed in all patients.Fifty-five patients were included in this study. The reasons for refractoriness were resistant recurrence to imidazole drugs (50 cases, 90.9%) and difficulty in cleaning the external auditory canal (5 cases, 9.1%). The most common strain was Aspergillus terreus (50.9%), followed by Aspergillus flavus (29.1%), Aspergillus niger (10.9%), and Aspergillus fumigatus (9.1%). After 2 weeks of treatment with 1% topical voriconazole drops, otomycosis in all patients was resolved. There was no significant change in bone conduction before and after topical voriconazole treatment (paired t-test, P = 0.5023; linear correlation analysis, R2 = 0.98; equation, y = 1.003x-0.284). Adverse effects, such as blurred vision and phototoxicity, were not observed in any patient.Administration of 1% topical voriconazole drops was effective and safe in the treatment of refractory otomycosis without tympanic membrane perforation within 2 weeks.
科研通智能强力驱动
Strongly Powered by AbleSci AI